Sichenzia Ross Ference LLP represented Lexaria Bioscience Corp. on the deal.Lexaria Bioscience Corp., (NASDAQ: “LEXX”), a global innovator in drug delivery platforms, announced a $2.0 million public…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
